Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

numares. |One Sample - All Answers.

3

Locations: Boston, MA;
Regensburg, GE; Singapore

60+

employees of medical and
scientific disciplines

2004

Founded as a spin-off of
Regensburg University

2M+

analyses worldwide with numares
technology


Mastering Metabolite Constellations. |For Precision Diagnostics.

numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based medicine.

 

Our diagnostic test are based on the interpretation of biomarker in the metabolism, whose dynamics and relation to each other allow for predicting disease progression. These metabolite constellations create diagnostics of a new generation: non-invasive, timely and meaningful at manageable costs.

Company Milestones

2019

numares announces collaboration with Mayo Clinic Laboratories on the development of new diagnostic tests

2018

numares completes another financing round

2018

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

2017

Launch of AXINON® renalTX-SCORE®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation

2017

Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test

2016

1,000.000 performed analyses

2016

numares completes another financing round

2015

Launch of CE-marked IVD test AXINON® lipoFIT®-S100 for comprehensive NMR-based lipoprotein profiling

2014

600.000 performed analyses

2014

Successful completion of studies on kidney transplantation

2014

Cooperation with a German laboratory network: commissioning of a test system for lipoprotein profiling

2013

200.000 performed analyses

2013

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

2013

Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

2010

100.000 performed analyses

2009

Certification as per EN ISO 13485:2003

As off 2005

Measurements within large studies such as GRAPHIC and KORA

2004

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)

Leadership

“numares is a leader in multiple biomarker diagnostics using the power of machine learning. This is the next wave of novel, high-value clinical diagnostics, embodied by numares' AXINON® IVD System, which harnesses NMR to enable
real-world metabolomics.

Winton Gibbons MBA

President at numares GROUP Corp.

“The combination of metabolomics and MGS® to develop new, meaningful diagnostic solutions holds great potential. It is my aim making numares' disruptive diagnostic technology available to US customers.

Sean Keohane, MBA

Vice President US Marketing & Sales at numares GROUP Corp.

“The single biomarker-based medicine is at its limits. Exploiting the dynamics of metabolic biomarker constellations opens up undreamt-of possibilities to solve important medical questions.”

Maulik Shah

Chief Medical Officer at numares GROUP Corp.

You did not activate the necessary cookies for this content.

activate necessary cookies and show content